Johnson & Johnson single-done vaccine is 66% effective in global clinical trials

Johnson & Johnson said on Friday that its single-drug coronavirus vaccine was effective at 72% in clinical trials in the United States, 66% in Latin America, 57% in South Africa, and 66% overall, according to CNBC.